Ipilimumab pharmacotherapy in patients with metastatic melanoma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immune- logic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved and investigational therapies. However, the adverse effects associated with this medication are unique and often require management with steroids or other immunosuppressants. In addition, the time to response differs with ipilimumab as compared to traditional chemotherapy, and alternative means of assessment of response have been proposed. In this review, we will summarize the basic science of this treatment, its preclinical evaluation, and the clinical trials leading to its approval. We will also discuss the details regarding its use, assessment of response to this drug and other immune-related therapies, and further directions for investigation.

Original languageEnglish (US)
Pages (from-to)275-286
Number of pages12
JournalClinical Medicine Insights: Oncology
Volume6
DOIs
StatePublished - 2012

Fingerprint

Melanoma
Drug Therapy
Investigational Therapies
Immunosuppressive Agents
Therapeutics
Steroids
Monoclonal Antibodies
Clinical Trials
Survival
Pharmaceutical Preparations
ipilimumab
Direction compound

Keywords

  • CTLA-4
  • Ipilimumab
  • Melanoma
  • Yervoy™

ASJC Scopus subject areas

  • Oncology

Cite this

@article{0cd4166b44b84e46ae2d6eb6b826323b,
title = "Ipilimumab pharmacotherapy in patients with metastatic melanoma",
abstract = "Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immune- logic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved and investigational therapies. However, the adverse effects associated with this medication are unique and often require management with steroids or other immunosuppressants. In addition, the time to response differs with ipilimumab as compared to traditional chemotherapy, and alternative means of assessment of response have been proposed. In this review, we will summarize the basic science of this treatment, its preclinical evaluation, and the clinical trials leading to its approval. We will also discuss the details regarding its use, assessment of response to this drug and other immune-related therapies, and further directions for investigation.",
keywords = "CTLA-4, Ipilimumab, Melanoma, Yervoy™",
author = "Jeter, {Joanne M} and Cranmer, {Lee D} and Hersh, {Evan M}",
year = "2012",
doi = "10.4137/CMO.S7245",
language = "English (US)",
volume = "6",
pages = "275--286",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Ipilimumab pharmacotherapy in patients with metastatic melanoma

AU - Jeter, Joanne M

AU - Cranmer, Lee D

AU - Hersh, Evan M

PY - 2012

Y1 - 2012

N2 - Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immune- logic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved and investigational therapies. However, the adverse effects associated with this medication are unique and often require management with steroids or other immunosuppressants. In addition, the time to response differs with ipilimumab as compared to traditional chemotherapy, and alternative means of assessment of response have been proposed. In this review, we will summarize the basic science of this treatment, its preclinical evaluation, and the clinical trials leading to its approval. We will also discuss the details regarding its use, assessment of response to this drug and other immune-related therapies, and further directions for investigation.

AB - Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immune- logic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved and investigational therapies. However, the adverse effects associated with this medication are unique and often require management with steroids or other immunosuppressants. In addition, the time to response differs with ipilimumab as compared to traditional chemotherapy, and alternative means of assessment of response have been proposed. In this review, we will summarize the basic science of this treatment, its preclinical evaluation, and the clinical trials leading to its approval. We will also discuss the details regarding its use, assessment of response to this drug and other immune-related therapies, and further directions for investigation.

KW - CTLA-4

KW - Ipilimumab

KW - Melanoma

KW - Yervoy™

UR - http://www.scopus.com/inward/record.url?scp=84865047961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865047961&partnerID=8YFLogxK

U2 - 10.4137/CMO.S7245

DO - 10.4137/CMO.S7245

M3 - Article

C2 - 22904648

AN - SCOPUS:84865047961

VL - 6

SP - 275

EP - 286

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -